Patents by Inventor Kai-Hsin LIAO

Kai-Hsin LIAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS, THERAPIES AND USES FOR TREATING CANCER
    Publication number: 20230340137
    Abstract: The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.
    Type: Application
    Filed: September 10, 2021
    Publication date: October 26, 2023
    Applicant: PFIZER INC.
    Inventors: Nathalie Annie BARDY BOUXIN, Eloisa Virginia BARRY, John Andrew BLAKE-HASKINS, Geoffrey Wing-Lynn CHAN, Jeffrey CHOU, Mohamed A ELMELIEGY, Heike Iris KRUPKA, Kai Hsin LIAO, Erik Rene VANDENDRIES, Andrea VIQUEIRA, Paul Stephen WISSEL, Anne YVER
  • METHODS, THERAPIES AND USES FOR TREATING CANCER
    Publication number: 20230192878
    Abstract: The present disclosure describes single agent and combination therapies and uses for the treatment of cancer and/or cancer-associated diseases. The single agent and combinations therapies include a BCMA antibody.
    Type: Application
    Filed: May 13, 2021
    Publication date: June 22, 2023
    Applicant: PFIZER INC.
    Inventors: Nathalie Annie BARDY BOUXIN, Eloisa Virginia BARRY, John Andrew BLAKE-HASKINS, Geoffrey Wing-Lynn CHAN, Jeffrey CHOU, Mohamed A ELMELIEGY, Heike Iris KRUPKA, Kai Hsin LIAO, Erik Rene VANDENDRIES, Andrea VIQUEIRA, Paul Stephen WISSEL, Anne YVER
  • ONCE DAILY CANCER TREATMENT REGIMEN WITH A PRMT5 INHIBITOR
    Publication number: 20230043985
    Abstract: A method of treating cancers, including pancreatic cancer, endometrial cancer, non-small cell lung cancer (NSCLC), endometrial cancer, cervical cancer, bladder cancer, head and neck squamous cell carcinoma (HNSCC), urothelial carcinoma, esophageal cancer, and other cancers, the method comprising once-daily administration, to a patient in need thereof, of a therapeutically effective amount of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroiso quinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl) cyclopentane-1,2-diol having the structure: Formula I or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 15, 2020
    Publication date: February 9, 2023
    Applicant: Pfizer Inc.
    Inventors: Meng LI, Kai-Hsin LIAO, Shinji YAMAZAKI